US Patent

US8299057 — Substituted indazole derivatives active as kinase inhibitors

Composition of Matter · Assigned to Nerviano Medical Sciences SRL · Expires 2032-03-10 · 6y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of substituted indazole derivatives that can be used as kinase inhibitors, particularly in the treatment of cancer.

USPTO Abstract

Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US8299057
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-03-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.